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SUMMARY     
Chronic pulmonary aspergillosis (CPA) is slowly progressive inflammatory pulmonary 
syndrome due to Aspergillus spp. The evidence regarding CPA treatment is limited. We 
conducted a randomized, multicenter, open-label trial comparing intravenous micafungin 
(MCFG) of 150-300 mg once daily with intravenous voriconazole (VRCZ) of 6 mg/kg 
twice on Day 1 followed by 4 mg/kg twice daily for the treatment of 107 inpatients with 
CPA to compare the efficacy and safety of both drugs as initial treatment in Japan. 
Treatment effectiveness was defined by clinical, mycological, radiological and serological 
responses 2 weeks after the initial administration and at the end of therapy. The total of 50 
and 47 patients were assigned to the MCFG and VRCZ groups, respectively. The 
difference in efficacy rates between MCFG and VRCZ was not significant, either after 2 
weeks [68.0% vs. 58.7%; the absolute difference, 9.3% with a 95% confidence interval 
(CI), -9.97 to 28.58, P=0.344] or at the end of therapy (60.0% vs. 53.2%; the absolute 
difference, 6.8% with a 95% CI, -12.92 to 26.54, P=0.499). In the safety evaluation, fewer 
adverse events occurred in the MCFG than VRCZ group (26.4% vs. 61.1%, P=0.0004). 
MCFG was as effective as VRCZ and significantly safer than as an initial treatment of 
CPA. (UMIN Clinical Trials Registry number, UMIN000001786.) 
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Chronic forms of pulmonary aspergillosis (CPA) are characterized as a slowly 
progressive inflammatory pulmonary syndrome due to Aspergillus spp.1, 2 Several names 
of these chronic forms of disease have been proposed: semi-invasive aspergillosis3, 
chronic necrotizing pulmonary aspergillosis (CNPA)4, simple or complex aspergilloma, 
and chronic cavitary and fibrosing pulmonary aspergillosis (CCPA and CFPA).5 As Hope 
et al.6 indicated apparently distinct entities do not exist for this syndrome and these forms 
usually overlap. The common characteristics of these forms, however, consist of 1) 
underlying pulmonary disorders, 2) the status of low-grade immunosuppression, and 3) 
less than severe findings of angioinvasion in histopathology. 1, 5, 7  
Numerous clinical cases and few retrospective studies have been reported for the 
treatment of CPA8-12; however, there are no large-scale clinical trials have been conducted. 
Although the latest Infectious Diseases Society of America (IDSA) guidelines for the 
treatment of aspergillosis recommend oral azoles for CPA as primary treatment 13, the 
utility of antifungal injections for CPA treatment is not known. Intravenous antifungal 
agents may possess important role as an induction therapy followed by oral antifungal 
drugs as maintenance therapy for CPA cases. Several kinds of intravenous antifungal 
agents active to Aspergillus spp. are available. Micafungin (MCFG) is new semisynthetic 
lipopeptide antifungal drug in the echinocandin family that has been developed in Japan.14 
Several in vitro and in vivo studies have shown high levels of antifungal activity against 
Aspergillus spp.15-17 Voriconazole (VRCZ), from a newer generation of triazoles, has also 
potent anti-aspergillus activity in vivo and in vitro. 18,19    
Our study is the first prospective large-scale trial comparing intravenous MCFG and 




From April 1, 2006, to November 30, 2008, we enrolled patients with CPA at 24 
Japanese hospitals in this study, which was approved by the ethics committee at each 
hospital. Every patient provided written informed consent. Astellas, Co. Ltd. (Tokyo, 
Japan) supported the study with a grant; Astellas, Co. Ltd. was not involved in the design 
of study, the enrollment of patients, the collection, analysis, interpretation of the data or 
preparation of the manuscript. All authors vouch for the completeness and accuracy of the 
data presented. 
Patients were eligible for enrollment if they were at least 20 years old and had been given 
a diagnosis of CPA. The diagnostic criteria of Hope et al. for CPA including chronic 
CNPA, CCPA, CFPA and complex aspergilloma were used in this study.6 Proposed 
enrollment criteria for prospective clinical studies of CPA by Denning with minor 
modifications were used for this trial.5 Patients with CPA had to fulfill the following 
conditions: (1) the existence of at least one of the symptoms in the complex consisting of 
fever, weight loss, sputum, cough, hemoptysis, fatigue, and shortness of breath; (2) new 
infiltrates, cavity formation, or expansion of pre-existing cavities with or without 
peri-cavitary infiltrates and adjacent pleural thickening; (3) at least one positive result of 
serologic tests including the Platelia Aspergillus test (Fujirebio, Tokyo, Japan) for 
detecting Aspergillus galactomannan antigen by enzyme-linked immunosorbent assay 
(cut-off value, 1.0), the Aspergillus immunodiffusion system (Microgen Bioproducts, Ltd., 
Camberley, United Kingdom) for anti-Aspergillus antibody detection, and the 
(1,3)--D-glucan test (cut-off value, 11.0 pg/ml; Wako Pure Chemical Industries, Osaka, 
Japan ; and cut-off value, 20 pg/ml for the Fungitec G Test, Seikagaku Corporation, Tokyo, 
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Japan) and/or any positive evidence of the existence of Aspergillus spp. by molecular 
diagnosis, culture, or pathological findings; (4) positive findings of at least one of the 
inflammation markers such as white blood cell (WBC) counts, value of C-reactive protein 
(CRP), and erythrocyte sedimentation rate (ESR); (5) lack of improvement of symptoms 
or signs after at least 3 days administration of broad-spectrum antibiotics. The following 
patients were excluded from the study: (1) patients who received MCFG or VRCZ within 
one month before the time of enrollment, (2) patients with simple aspergilloma, invasive 
pulmonary aspergillosis, or allergic bronchopulmonary aspergillosis, (3) patients with 
infectious diseases other than aspergillosis, (4) pregnant patients, (5) patients who did not 
provide informed consent, and (6) patients with liver, kidney, or heart failure, which 
fulfilled the Grade II level defined in the Common Toxicity Criteria grading system of the 
National Cancer Institute.20 
 
Procedures 
The patients were allocated to either the MCFG or VRCZ treatment group. The 
randomization of the minimization method was performed at a centralized web site by 
attending physicians after obtaining the informed consent from each patient. Random 
numbers were generated by the computer. Stratification factors of severity and past history 
of treatment of CPA including aspergilloma were used. Severity was defined as mild, 
moderate and severe. The factors that were used for determining severity were (1) serum 
albumin value (less than 2.5 g/dl), (2) SpO2 less than 90% or PaO2 less than 60 Torr, (3) 
impaired oral administration of drugs, (4) expansion of newer infiltration shadow on chest 
X-ray film that was more than half of the lung field, (5) the existence of severe 
complications such as malignancies, cerebral vascular disorders, hepatic diseases, kidney 
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diseases or heart failure, and (6) administration of corticosteroids. Mild severity was 
defined as the patient possessing none of the above factors. Moderate severity was defined 
as the patient possessing only one of the factors listed above. Severe severity was defined 
as the patient possessing at least two of the factors listed above. The randomization 
schedule was generated by a computer to ensure balanced treatment allocation. Briefly, 
when the difference of number of allocated patients between the MCFG and VRCZ groups 
was less than two, the patients were completely randomized. Hence, when the difference 
was more than three, the patients were allocated to the smaller number therapy group at 
90% probability or the bigger number therapy group at 10% probability. 
VRCZ was given intravenously at 6 mg/kg every 12 h for 24 h, and then 4 mg/kg every 
12 h. MCFG was given at 150-300 mg per day. Dose of MCFG was accepted to be 
decreased due to patient’s body weight by the decision of the attending physician. The 
reason that the dose of MCFG was not fixed in this study was that no data was available 
about the dose effect of MCFG in the treatment of pulmonary aspergillosis. Patients 
received treatment for at least 2 weeks with a maximum duration of 4 weeks.  
 Patients were followed up until 4 weeks after the first administration. Clinical 
assessments were made daily during treatment. Clinical laboratory tests were run once 
every week. Radiological and mycological investigations were performed at 2 weeks and 
at the end of treatment with a maximum 4 weeks. Concurrent treatment with antibiotics 
was prohibited in this study. 
The primary efficacy end point was response to treatment, which was classified as 
‘success’ or ‘failure’ at the end of administration (at least 2 weeks of administration with a 
maximum duration of 4 weeks). Each case was carefully reviewed by the investigators. All 
clinical response criteria were defined as previously reported with slight modifications.8 
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Briefly, four groups of factors, consisting of (1) clinical, (2) laboratory, (3) radiological, 
and (4) mycological, were assessed. The efficacy was evaluated for each of the four 
groups of factors regardless of whether there was a partial or complete response. (1) 
Clinical factors were clinical symptoms and signs such as hemosputum, cough, dyspnea 
and fever which were recorded individually by attending physicians and assessed by a 
data-review committee. Clinical improvement was defined by reduction or disappearing of 
these symptoms or signs. (2) Laboratory data such as CRP level, WBC counts, and ESR 
were independently assessed by a data-review committee. Laboratory data improvement 
was defined by reduction levels of these inflammatory markers. The transition of titer of 
anti-Aspergillus antibody was not evaluated. (3) Radiological factors were also evaluated 
individually by a data-review committee. Briefly, improvement was defined only if there 
was apparent improvement in the newly appeared lesions on radiological images; no 
transitional changes in lesions, were not considered improvements (4) Mycological factors 
were determined by culture or histopathological tests using clinical samples such as 
sputum, bronchoalveolar lavage fluid, and percutaneous aspiration biopsy samples. 
Mycological improvement was defined by disappearing of Aspergillus from clinical 
samples. The members of the data-review committee were not blinded to the treatment 
assignment on the evaluation of the outcomes or side effects. 
A ‘success’ with respect to clinical response at the end of the treatment was defined as 
follows: improvement in at least two of the four groups of factors without deterioration in 
other two groups of factors. A ‘failure’ was defined as a clinical response that did not 
match with the ‘success’ definition. 
 The secondary efficacy end point was response to treatment, which was classified as 
‘success’ or ‘failure’ at the end of 2 weeks administration. All four groups of factors were 
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used as in the primary endpoint; however, the criterion of “success” was changed as 
follows: improvement in at least one of the four groups of factors without deterioration in 
other groups of factors. 
Adverse events were recorded from randomization until the last day of treatment. These 
events were classified according to the Common Toxicity Criteria grading system of the 
National Cancer Institute.20  
 
Statistical analysis 
The primary objective was to show the superiority of each drug in the per-protocol 
population. Because number of CPA patients, data for the efficacy of antifungals to CPA 
and budget were limited, the sample size for this clinical trial was set on the basis of the 
frequency of adverse events of both drugs. On the basis of the rate of adverse events, 
which averaged 35% for MCFG and 62% for VRCZ, a power of 0.80 and the requirement 
to show the superiority of one drug to the comparator group with a significance of 5.0% 
for the final analysis were set. A total sample size of 100 patients (50 assigned MCFG and 
50 assigned VRCZ) satisfying the criteria for the per-protocol population was calculated to 
be necessary.  
The intention-to-treat population was defined as patients who underwent randomization. 
The modified intention-to-treat population was defined as patients who received at least 
one dose of the study drug they were initially assigned to receive and who had a baseline 
diagnosis of CPA. The per-protocol population was defined as patients who were 
confirmed to have a baseline diagnosis of CPA, the availability of an investigator's 
assessment of over all treatment at the end of therapy, at least 14 doses of one of the study 
drugs, and no prohibited medication. The population included in the safety analysis 
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consisted of all patients who received their initial study drug. The investigator’s 
assessments of overall treatment success at the end of therapy and at the end of the first 2 
weeks were analyzed with a two-sided 95% confidence intervals (CI). Non-inferiority of 
MCFG could be concluded if the two-sided 95% CI for the difference in the proportions 
(MCFG minus VRCZ) had a lower boundary above –15%. Categorical variables were 
tested by the Fisher's exact test and were expressed as frequencies and proportions. 
Continuous variables were tested by the Student’s t-test and were expressed as means and 
ranges. A P-value of <0.05 was considered statistically significant. 
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RESULTS 
Enrollment and baseline characteristics of the patients 
A total of 107 patients were recruited by 24 centers in Japan during study period. A total 
of 53 and 54 patients were assigned to the MCFG and VRCZ group, respectively; these 
patients comprised the intention-to-treat population. Trial profile was presented in Figure 
1. All 107 patients were recruited for safety analysis. Four and six patients were excluded 
from the intention-to-treat population and the modified intention-to-treat population, 
respectively. One case in the VRCZ-treated group lacked the assessment data at the first 2 
weeks of treatment; therefore, this case was not evaluated at the secondary endpoint but 
was evaluated at the primary endpoint. The demographic characteristics and underlying 
conditions of the patients in the intention-to-treat population are summarized in Table 1. 
The MCFG and VRCZ groups were well matched and no significance difference was 
observed in the intention-to-treat and modified intention-to-treat populations (data not 
shown). 
 
Base-line characteristics of the infection and the serological findings 
Characteristics of the patients with CPA such as symptoms, signs, and inflammation 
markers and the results of the serum tests prior to the administration of study drugs in the 
per-protocol populations are summarized in Table 2. There were no significant differences 
in the clinical characteristics including symptoms, laboratory findings and the serological 
test result between the MCFG and VRCZ groups. 
The results of the culture test and biopsy of respiratory specimens are shown in Table 3. 




The average administration time was 23.6 days for the MCFG group and 20.6 days for 
the VRCZ group without statistical difference (P=0.105). The average dose of MCFG was 
167.4 mg/day (range, 75 – 300 mg/day) and that for VRCZ was 8 mg/kg/day (range, 214 – 
613 mg/day). There were four cases, in which 300 mg/day of MCFG was used in this 
study by the decision of the attending physicians. There was a single case in which 75 
mg/day of MCFG was used due to low body weight of the patient. No single patient 
underwent surgical resection of the pulmonary legions in this study during the evaluation 
therapy. 
The outcome at end of treatment in the per-protocol populations was not significantly 
different between the MCFG and VRCZ group (Table 4). In the intention-to-treat 
population, success rates were 56.6% (30 of 53 patients) with MCFG and 46.3% (25 of 54 
patients) with VRCZ (absolute difference, 10.3%; 95% CI, -8.63 to 29.25). The response 
rates of each group of factors, (clinical, laboratory, radiological, and mycological) are 
shown in Table 4. There was no significant difference in the response rates among all 
factors between the MCFG and VRCZ groups.  
The outcome at the end of the first 2 weeks of treatment was not significantly different 
between the MCFG and the VRCZ group. In the intention-to-treat population, success 
rates were 64.2% (34 of 53 patients) with MCFG and 50.0% (27 of 54 patients) with 
VRCZ (absolute difference, 14.2%; 95% CI, -4.61 to 32.91). The response rates of the 
four groups of evaluated factors were not significantly different (Table 4).  
Because the lower 95%confidence limit for the difference between MCFG and VRCZ at 
both endpoints settings was below zero, MCFG was considered to be neither inferior nor 
superior to VRCZ. 
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Safety 
Table 5 shows the treatment-related adverse events and reasons for discontinuation from 
the study in patients who received at least one dose of study drug. Significantly fewer 
adverse effects were observed in the MCFG group than in the VRCZ group. Hepatic 
events were the most frequent adverse events in both the MCFG and VRCZ groups (8 
cases in the MCFG group and 15 cases in the VRCZ group). There were four cases in 
which VRCZ was discontinued due to severe hepatic events (at least one of the values of 
glutamic oxaloacetic transamidase, glutamic pyruvic transamidase, alkaline phosphatase, 
or gamma-glutamyl transpeptidase exceeded 2.5 times the value of the upper normal limit). 
Various visual events including photophobia, xanthopsia, abnormal vision, defective color 
vision, vision blurred, and visual disturbance occurred only in the VRCZ group and all 
visual events were transient and resolved without intervention. All of the adverse effects 
other than visual events recovered during the treatment or after the end of treatment, 
except in one case with alkaline phosphatase elevation, which was mild.
 14
DISCUSSION 
In the current study, we recruited patients who basically satisfied the criteria for the 
clinical study of CPA proposed by Denning et al. 5 The inclusion criteria in this study were 
designed to recruit patients who required immediate treatment. Another consideration was 
made using broad-spectrum antibiotics prior to registration to minimize registering 
patients with bacterial infections in addition to aspergillosis.  
The latest IDSA guidelines for the treatment of aspergillosis recommend oral VRCZ or 
ITCZ for CPA as primary treatment 13, however there is no a large-scale clinical trial data 
to support recommendation. Although the utility of antifungal injections for CPA treatment 
is not known, intravenous antifungal agents may be used as an induction therapy followed 
by oral antifungal drugs as maintenance therapy for CPA cases. Additionally, intravenous 
antifungal drugs will be needed if the patients are refractory to oral antifungal drugs or in 
severe status. Our study is the first large-scale clinical trial comparing intravenous MCFG 
and intravenous VRCZ as induction therapy in CPA patients who require immediate 
treatment. It may be ideal to use intravenous drugs as long as possible, however longer 
usage is not reasonable due to its high cost. Our study design was to use intravenous 
antifungals for several weeks (max 4 weeks) in order to see these antifungals may have 
power to stabilize or improve clinical status of CPA patients with active inflammatory 
signs. 
The reason that the treatment success rates of both MCFG and VRCZ were decreased at 
the end of treatment compared to those of the first 2 weeks of administration is that the 
definition of treatment success was different. The criteria for “success” at the end of 
treatment were stricter than those after 2 weeks of administration by the protocol. No 
deterioration and improvement in at least two of the clinical, laboratory, radiological, and 
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mycological factors were required for “success” clinical efficacy assessment at the end of 
therapy. Lack of improvement in two factors was still allowed if the other two factors 
were improved for the “success” evaluation after 2 weeks of administration. The number 
of deterioration cases in clinical, radiological, and mycological factors was few at 2 weeks 
and the end of treatment. However, 20% to 30% of all cases showed deterioration in 
laboratory factors in both the MCFG and VRCZ groups at 2 weeks and the end of the 
treatment, although there were no statistical differences between the MCFG and VRCZ 
groups (data not shown). These data indicated that the effective rate at 2 weeks and the 
end of treatment of both drugs might be increased if the serological factors were not 
counted for evaluation. Because the clinical aspects of CPA are complicated, establishing a 
reasonable assessment system of the clinical effectiveness of antifungals with objective 
factors is also challenging. The limitation of this study is that there was no longer 
follow-up data after the discontinuation of the intravenous drugs. Many of the patients had 
received the following oral antifungals such as ITCZ capsules or VRCZ tablets after the 
trial. The relapse rate is important for understanding an ultimate outcome of the patients 
with CPA and required in the future study.  
The overall effective rate of both drugs however, was only around 60% with average 
duration periods about 3 weeks. The response rates of evaluation factors after the first 2 
weeks and at the end of treatment indicated that longer treatment will increase the 
response rate of all factors with almost 10% of improve rate gained except Aspergillus 
eradication. There were four cases in which a high dose of MCFG (300 mg/day) was used 
in this study. Three of four patients were successfully treated and there were no major 
adverse reactions. However, this data is not showing dose effect of MCFG, the population 
of patients taking a high dose of MCFG is too small to compare the dose effect of MCFG 
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in patients with CPA. 
Our results indicated apparently fewer adverse effects in the MCFG than VRCZ group, 
even though the average administration period was longer by 3 days. The incidence rate of 
adverse events was still significantly lower in MCFG group even with exclusion of visual 
events, which are unique to VRCZ. VRCZ is metabolized via the cytochrome P450 (CYP) 
2C19 isozyme in liver21 and the CYP2C19 mutant type is generally found in 60% - 70% 
of Asian populations including Japanese,22 which indicates that these poor metabolizers of 
VRCZ are likely to have more serious liver dysfunction. Our current data showed 
significantly more occurrence of liver dysfunction in the VRCZ than MCFG group. 
Although the MCFG group showed a lower incidence rate of adverse effects, one case 
with disseminated intravascular coagulation (DIC) was reported as a severe adverse effect. 
DIC occurred 4 days after the discontinuation of MCFG in this case and the patient 
recovered. Monitoring blood concentration of VRCZ, not performed in current study, 
might support further understanding of frequency and severity of adverse effects. 
Our study also revealed the important clinical aspects of patients with CPA in Japan. 
The mean age of the patients with CPA was 70.9 years old and most patients were men 
with malnutrition and pulmonary complications, especially tuberculosis sequelae. Smith et 
al. showed that tuberculosis sequelae are also a major risk factor in patients with CPA in 
United Kingdom23. Only the Aspergillus antibody test by the Aspergillus immunodiffusion 
system showed a reasonably high positive rate with 88.6% of all patients, which 
resembled the previous results by Denning et al.2, 5 The common serum antigen detecting 
tools for invasive Aspergillus infection are not suitable for CPA diagnosis.  
In conclusion, this first large-scale prospective clinical trial comparing intravenous 
MCFG and VRCZ for patients with CPA indicated that MCFG and VRCZ showed good 
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effectiveness without statistical difference, although significantly fewer adverse effects 
were observed in the MCFG group.
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APPENDIX 
 Astellas, Co. Ltd. (Tokyo, Japan) supported the study with a grant; the sponsor was not 
involved in the design of study, the enrollment of patients, the collection, analysis, 
interpretation of the data or preparation of the manuscript.  
The following is a list of JCPASG investigators: Yasuhiro Yamazaki, National Hospital 
Organization Dohoku National Hospital, Asahikawa; Kunihiko Yoshimura, Toranomon 
Hospital, Tokyo; Takashi Ogura, Kanagawa Cardiovascular and Respiratory Center, 
Yokohama; Masahiro Shirai, National Hospital Organization Tenryu Hospital, 
Hamamatsu; Tatsuo Kato, National Hospital Organization Nagara Medical Center, Gifu; 
Hiroyuki Taniguchi, Tosei General Hospital, Seto; Hidenori Ibata, National Hospital 
Organization Mie Chuo Medical Center, Tsu; Michiaki Mishima, Kyoto University 
Hospital, Kyoto; Yoshio Taguchi, Tenri Hospital, Tenri; Yoshiro Mochiduki, National 
Hospital Organization Himeji Medical Center, Himeji; Yuji Sugimoto, Tottori Prefecture 
Central Hospital, Tottori; Tadashi Ishida, Kawasaki Hospital, Okayama; Hiroshi Miyawaki, 
Kagawa Prefectural Central Hospital, Takamatsu; Yuichi Fukuda, Kitakyushu City Yahata 
Hospital, Kitakyushu; Kiyoyasu Fukushima, Japanese Red Cross Nagasaki Genbaku 
Isahaya Hospital, Isahaya; Yuichi Inoue, Isahaya Health Insurance General Hospital, 
Isahaya; Sawai Toyomitsu, Sasebo City General Hospital, Sasebo; Jun-ichi Kadota, Oita 
University Hospital, Oita; Shigeki Nakamura, National Hospital Organization Ureshino 
Medical Center, Ureshino – all in Japan.
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Table 1. Characteristics of the patients in the intention-to-treat population   
          
characteristic overall (n=107) micafungin (n=53) voriconazole (n=54) P 
Age - yr     
  Mean 70.9 72.1 69.9 0.163 
  Range 47 - 88 48 - 87 50 - 88  
     
Sex - no. (%)     
  Male 83 (77.6) 37 (69.8) 46 (85.2) 0.057 
  Female 24 (22.4) 16 (30.2) 8 (14.8)  
     
Height - cm     
  Mean 159.5 159.3 159.6 0.447 
  Range 134.5 - 179.0 138.0 - 179.0  134.5 - 169.5   
     
Weight - kg     
  Mean 45.7 44.9 46.4 0.831 
  Range 28.0 - 74.2 28.0 - 68.0 29.1 - 74.2  
     
Underlying condition - no. (%)     
  Tuberculosis sequelae 56 (52.3) 30 (56.6) 26 (48.1) 0.441 
  Chronic obstructive pulmonary disease 22 (20.6) 10 (18.9) 12 (22.2) 0.812 
  Diabetes 13 (12.1) 4 (7.5) 9 (16.7) 0.236 
  Others 16 (43.0) 22 (41.5) 24 (44.4) 0.520 
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Table 2. Clinical characteristics, laboratory and serological findings of the patients in 
the per-protocol population 
      
characteristic overall micafungin voriconazole P 
Body temperature (℃)     
  Number of cases evaluated 95 48 47  
  Mean 37.1 37.0 37.2 0.094 
  Range 36.2 -39.0 36.2 -38.2 35.3 - 39.0  
     
Respiration rate (/ min)     
  Number of cases evaluated 61 28 33  
  Mean 19.7 18.8 20.5 0.181 
  Range 12.0 - 38.0 12.0 - 28.0 12.0 - 38.0   
     
Symptoms (%)     
  Number of cases evaluated 97 50 47  
  Cough 86 (88.7) 45 (90.0) 41 (87.2)  
  Sputum 82 (84.5) 45 (90.0) 37 (78.3)  
  Hemosputum 13 (13.4) 7 (14.0) 6 (12.8)  
  Hemoptysis 0 (0) 0 (0) 0 (0)  
     
SpO2 (%)     
  Number of cases evaluated 92 47 45  
  Mean 96.5 96.6 96.3 0.304 
  Range 92.0 - 100.0 92.0 - 100.0 93.0 - 99.0  
     
WBC (/mm3)     
  Number of cases evaluated 97 50 47  
  Mean 7381.4 7051.8 7732.1 0.308 







     
CRP (mg/dl)     
  Number of cases evaluated 94 49 45  
  Mean 4.8 4.3 5.4 0.277 
  Range 0.0 - 21.0 0.0 - 16.9 0.1 - 21.0  
     
ESR (mm/hr)     
  Number of cases evaluated 59 30 29  
  Mean 79.8 84.0 75.4 0.408 
  Range 7.0 - 156.9 16.0 - 138.0 7.0 - 156.9  
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-D-glucan / WAKO (pg/ml)    
  Number of cases tested 47 24 23  
  Positive 9 (19.1 %) 7 (29.2 %) 2 (8.7 %) 0.137 
  Mean 12.5 17.7 7.1  
  Range 0.6 - 158.3 0.6 - 158.3 1.0 - 33.8  
     
-D-glucan / Fungitec G test (pg/ml)    
  Number of cases tested 40 19 21  
  Positive 11 (27.5 %) 5 (26.3 %) 6 (28.6 %) 1.000 
  Mean 24.1 22.0 26.0  
  Range 0.8-171.0 5.0 - 83.0 0.8 -171.0  
     
Platelia Aspergillus test     
  Number of cases tested 79 41 38  
  Mean 0.75 0.8 0.7 0.570 
  Range 0.1 - 5.0 0.1 - 5.0 0.1 - 3.9  
     
Platelia Aspergillus test (%) cut off: 1.0    
  Number of cases tested 88 46 42  
  Positive 24 (27.3 %) 15 (32.6 %) 9 (21.4 %) 0.338 
     
Aspergillus immunodiffusion system (%)    
  Number of cases tested 79 40 39  
  Positive 70 (88.6 %) 36 (90.0 %) 34 (87.2 %) 0.737 
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Table 3. Mycological findings of patients in the per-protocol population 
  
overall 
(n=84) micafungin (n=45) voriconazole (n=39) 
CULTURE    
A. fumigatus 30 (35.7 %) 18 12 
A. niger 4 (4.8 %) 0 4 
A. terreus 1 (1.2 %) 1 0 
Aspergillus spp. 7 (8.3 %) 3 4 
overall Aspergillus spp. 42 (50.0 %) 22 20 
    
BIOPSY    
filamentous fungi 2 (2.4 %) 1 1 
n: number of cases in which culture tests were performed on any respiratory 
specimen. 
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Table 4. Treatment success and response rate of clinical, laboratory findings, radiological, and mycological factors at the 
end of the treatment and two weeks after initial administration in the per-protocol population 
          
  micafungin voriconazole Difference in proportion (95% CI) P 
At the end of treatment (primary endpoint)     
  Number treated successfully (%) 30 (60.0) 25 (53.2) 6.8 % (-12.92 to 26.54) 0.543 
  Clinical 35 (70.0) 34 (72.3) - 0.826 
  Laboratory findings 25 (50.0) 25 (53.2) - 0.840 
  Radiological 25 (50.0) 21 (44.7) - 0.685 
  Mycological 9 (18.0) 8 (17.0) - 1.000 
     
At the first two weeks (secondary endpoint)     
  Number treated successfully (%) 34 (68.0) 27 (58.7) 9.3 % (- 9.97 to 28.58) 0.399 
  Clinical 29 (58.0) 27 (58.7) - 1.000 
  Laboratory findings 24 (48.0) 20 (43.5) - 0.686 
  Radiological 20 (40.0) 16 (34.8) - 0.675 




Table 5. Treatment-related adverse events and reasons for discontinuation from study of patients who received at least one 
dose of study drug 
  
micafungin 
(n=53)   
voriconazole 
(n=54) P 
Serious 1 (1.9 %) Serious 4 (7.4 %)  
  Disseminated intravascular 
coagulation 1 (1.9 %)   Ventricular extrasystoles 1 (1.9 %)  
    Hepatic events 1 (1.9 %)  
    Dizziness 1 (1.9 %)  
    Nausea 1 (1.9 %)  
     
Treatment discontinuation 3 (5.7 %) Treatment discontinuation 7 (13.0 %)  
  Rash 2 (3.8 %)   Hepatic events 4 (7.4 %)  
  Vomiting 1 (1.9 %)   Hyperkalemia 1 (1.9 %)  
    Ventricular extrasystoles 1 (1.9 %)  
    Dizziness 1 (1.9 %)  
     
Overall 14 (26.4 %) Overall 33 (61.1 %) 0.0004
  Hepatic events 8 (15.1 %)   Hepatic events 19 (35.2 %) 0.025 
  Visual events 0 (0 %)   Visual events 15 (29.6 %) <0.0001
  Overall excluded visual events 14 (26.4 %) 
  Overall excluded visual 
events 27 (50 %) 0.012 
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  Rash 3 (5.7 %)   Hallucination 4 (7.4 %)  
  Vomiting 2 (3.8 %)   Dizziness 2 (3.7 %)  
  Renal events 1 (1.9 %)   Renal events 1 (1.9 %)  
  Blood pressure increased 1 (1.9 %)   Hyperkalemia 1 (1.9 %)  
  Eosinophil count increased 1 (1.9 %)   Ventricular extrasystoles 1 (1.9 %)  
  White blood cell count decreased 1 (1.9 %)   Pseudomembranous colitis 1 (1.9 %)  
  Disseminated intravascular 
coagulation 1 (1.9 %)   Nausea 1 (1.9 %)  
    Headache 1 (1.9 %)  
    Restlessness 1 (1.9 %)  
    Hemoptysis 1 (1.9 %)  
      Skin discoloration 1 (1.9 %)   
 
